ZA948013B - R-enantiomer of N-propargyl-1-aminoindan salts compositions and uses thereof - Google Patents
R-enantiomer of N-propargyl-1-aminoindan salts compositions and uses thereofInfo
- Publication number
- ZA948013B ZA948013B ZA948013A ZA948013A ZA948013B ZA 948013 B ZA948013 B ZA 948013B ZA 948013 A ZA948013 A ZA 948013A ZA 948013 A ZA948013 A ZA 948013A ZA 948013 B ZA948013 B ZA 948013B
- Authority
- ZA
- South Africa
- Prior art keywords
- propargyl
- aminoindan
- subject invention
- subject
- pharmaceutically acceptable
- Prior art date
Links
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical class C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000014674 injury Diseases 0.000 abstract 4
- 208000027418 Wounds and injury Diseases 0.000 abstract 3
- 230000006378 damage Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 231100000189 neurotoxic Toxicity 0.000 abstract 1
- 230000002887 neurotoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13951793A | 1993-10-18 | 1993-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA948013B true ZA948013B (en) | 1995-05-31 |
Family
ID=22487049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA948013A ZA948013B (en) | 1993-10-18 | 1994-10-13 | R-enantiomer of N-propargyl-1-aminoindan salts compositions and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0812190B1 (fr) |
| JP (3) | JPH09505806A (fr) |
| AT (1) | ATE284208T1 (fr) |
| AU (1) | AU1253495A (fr) |
| CA (1) | CA2174449C (fr) |
| DE (2) | DE122005000044I2 (fr) |
| DK (1) | DK0812190T3 (fr) |
| ES (1) | ES2235170T3 (fr) |
| FR (1) | FR05C0033I2 (fr) |
| HU (1) | HU226138B1 (fr) |
| IL (1) | IL111240A (fr) |
| LU (1) | LU91191I2 (fr) |
| MX (1) | MXPA94008019A (fr) |
| NL (1) | NL300205I2 (fr) |
| PT (1) | PT812190E (fr) |
| WO (1) | WO1995011016A1 (fr) |
| ZA (1) | ZA948013B (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US5844003A (en) * | 1991-04-04 | 1998-12-01 | Innovations Foundation | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
| DE4327516A1 (de) * | 1993-08-17 | 1995-02-23 | Asta Medica Ag | Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| EP0738149B1 (fr) * | 1994-01-10 | 2006-11-29 | Teva Pharmaceutical Industries, Ltd. | Derives de 1-amino-indane et leurs compositions |
| WO1996024346A1 (fr) * | 1995-02-10 | 1996-08-15 | The University Of Toronto Innovations Foundation | Composes deprenyle pour le traitement du glaucome |
| PL183266B1 (pl) * | 1995-03-02 | 2002-06-28 | Scherer Ltd R P | Doustna kompozycja farmaceutyczna,sposób wytwarzania doustnej kompozycji farmaceutycznej oraz zastosowanie doustnej kompozycji farmaceutycznej |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| DE69738275T2 (de) | 1996-12-18 | 2008-08-28 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
| WO1999037293A2 (fr) * | 1998-01-27 | 1999-07-29 | Thomas Thomas N | Procedes de traitement utilisant des inhibiteurs mao-a et mao-b tels que l-deprenyl |
| US6737547B1 (en) | 1998-12-31 | 2004-05-18 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using N-acyl-1H-aminoindenes |
| IL149308A0 (en) | 1999-10-27 | 2002-11-10 | Teva Pharma | Use of 1-aminoindan derivatives for treatment of manic disorders |
| EP1567152B1 (fr) * | 2002-11-15 | 2013-08-14 | Teva Pharmaceutical Industries Limited | Utilisation de la rasagiline avec du riluzole pour traiter la sclerose laterale amyotrophique |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| EP1588704A1 (fr) * | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie |
| CA2901244A1 (fr) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Preparations de rasagiline presentant une uniformite de teneur amelioree |
| JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| CN103142570A (zh) | 2005-12-09 | 2013-06-12 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 低剂量Ladostigil 用于神经保护的用途 |
| EP1991214B1 (fr) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Utilisation de rasagiline pour traiter une atrophie multisystématisée |
| TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| EP2007369A4 (fr) * | 2006-04-03 | 2009-07-01 | Teva Pharma | Utilisation de rasagiline pour le traitement du syndrome des jambes sans repos |
| EP1892233A1 (fr) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | De nouveaux sels de la substance active rasagiline |
| BRPI0718339A2 (pt) | 2006-12-14 | 2014-02-18 | Teva Pharma | Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina |
| RS52183B (sr) | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| WO2009032273A1 (fr) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries, Ltd. | Procédé pour traiter le glaucome avec la rasagiline |
| KR101523195B1 (ko) | 2007-12-24 | 2015-05-27 | 시플라 리미티드 | 프로파길화된 아미노인단 유도체의 합성방법 |
| WO2009122301A2 (fr) * | 2008-03-31 | 2009-10-08 | Actavis Group Ptc Ehf | Particules de mésylate de rasagiline et leur procédé de préparation |
| WO2009141737A2 (fr) * | 2008-05-23 | 2009-11-26 | Medichem, S.A. | Nouveau procédé d'obtention d'un dérivé de mésylate d'aminoindane |
| NZ589470A (en) * | 2008-06-02 | 2012-08-31 | Generics Uk Ltd | A process for the preparation of rasagiline and its analogues |
| AU2009254927B2 (en) | 2008-06-02 | 2014-03-13 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
| CA2727021A1 (fr) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Procede de purification de la base de la rasagiline |
| EA201170181A1 (ru) | 2008-07-11 | 2011-08-30 | Синтон Бв | Полиморфные формы разагилина гидрохлорида |
| AR074637A1 (es) * | 2008-07-18 | 2011-02-02 | Medichem Sa | Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| DK2451771T3 (da) * | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| CN102048717B (zh) † | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2325159A1 (fr) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Nouveaux sels de rasagiline |
| EP2515891A4 (fr) | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-céto-n-propargyl-1-aminoindane |
| US20120269871A1 (en) | 2009-12-30 | 2012-10-25 | Actavis Group Ptc Ehf | Solid state forms of rasagiline salts |
| CN102791258B (zh) * | 2010-02-03 | 2018-05-08 | 图必制药公司 | 雷沙吉兰的延长释放制剂及其用途 |
| WO2011121607A2 (fr) | 2010-03-29 | 2011-10-06 | Cadila Healthcare Limited | Composé de rasagiline et sels pharmaceutiquement acceptables de celui-ci |
| EP2389927A1 (fr) | 2010-05-30 | 2011-11-30 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Formulations pharmaceutiques de rasagiline |
| CN102464589A (zh) * | 2010-11-17 | 2012-05-23 | 凯瑞斯德生化(苏州)有限公司 | 雷沙吉兰、其甲磺酸盐及其中间体的制备方法 |
| EP2663545B1 (fr) | 2011-01-13 | 2015-07-01 | Nobel Ilaç Sanayii Ve Ticaret A.S. | Nouveau procédé de synthèse de rasagiline |
| EP2681186B1 (fr) | 2011-03-03 | 2016-05-11 | Synthon BV | Procédé de résolution de 1-aminoindane |
| EP2705021A2 (fr) | 2011-05-04 | 2014-03-12 | Cadila Healthcare Limited | Rasagiline et ses sels pharmaceutiquement acceptables |
| HK1200315A1 (en) * | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
| DE102012000786A1 (de) | 2012-01-18 | 2013-07-18 | Stada Arzneimittel Ag | Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin |
| EP2827848B1 (fr) | 2012-03-21 | 2016-04-27 | Synthon BV | Compositions pharmaceutiques stables comprenant des sels de la rasiligine |
| WO2013175493A1 (fr) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Compositions pharmaceutiques orales stables |
| EP2796130A3 (fr) | 2013-02-06 | 2015-02-25 | Galenicum Health S.L. | Comprimés à libération immédiate comprenant de l'hémitartrate de rasagiline |
| ES2502140T1 (es) | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Comprimidos de liberación inmediata de rasagilina hemitartrato |
| IN2013MU01782A (fr) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
| ES2042520T3 (es) * | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| IL99759A (en) * | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
-
1994
- 1994-10-11 IL IL11124094A patent/IL111240A/en not_active IP Right Cessation
- 1994-10-12 HU HU9601012A patent/HU226138B1/hu active Protection Beyond IP Right Term
- 1994-10-12 WO PCT/US1994/011567 patent/WO1995011016A1/fr not_active Ceased
- 1994-10-12 AU AU12534/95A patent/AU1253495A/en not_active Abandoned
- 1994-10-12 ES ES95903505T patent/ES2235170T3/es not_active Expired - Lifetime
- 1994-10-12 AT AT95903505T patent/ATE284208T1/de active
- 1994-10-12 DE DE200512000044 patent/DE122005000044I2/de active Active
- 1994-10-12 PT PT95903505T patent/PT812190E/pt unknown
- 1994-10-12 DE DE69434178T patent/DE69434178T2/de not_active Expired - Lifetime
- 1994-10-12 EP EP95903505A patent/EP0812190B1/fr not_active Expired - Lifetime
- 1994-10-12 JP JP7512014A patent/JPH09505806A/ja not_active Withdrawn
- 1994-10-12 DK DK95903505T patent/DK0812190T3/da active
- 1994-10-12 CA CA002174449A patent/CA2174449C/fr not_active Expired - Lifetime
- 1994-10-13 ZA ZA948013A patent/ZA948013B/xx unknown
- 1994-10-17 MX MXPA94008019A patent/MXPA94008019A/es active IP Right Grant
-
2002
- 2002-10-17 JP JP2002303097A patent/JP2003160481A/ja not_active Withdrawn
-
2005
- 2005-08-09 FR FR05C0033C patent/FR05C0033I2/fr active Active
- 2005-08-10 LU LU91191C patent/LU91191I2/fr unknown
- 2005-08-15 NL NL300205C patent/NL300205I2/nl unknown
-
2009
- 2009-09-24 JP JP2009219662A patent/JP2010018626A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2235170T3 (es) | 2005-07-01 |
| EP0812190B1 (fr) | 2004-12-08 |
| CA2174449A1 (fr) | 1995-04-27 |
| WO1995011016A1 (fr) | 1995-04-27 |
| HUT77934A (hu) | 1998-11-30 |
| ATE284208T1 (de) | 2004-12-15 |
| DE69434178T2 (de) | 2005-12-01 |
| IL111240A (en) | 2001-10-31 |
| FR05C0033I2 (fr) | 2006-12-29 |
| HU226138B1 (en) | 2008-05-28 |
| DK0812190T3 (da) | 2005-04-11 |
| EP0812190A4 (fr) | 1998-03-04 |
| EP0812190A1 (fr) | 1997-12-17 |
| PT812190E (pt) | 2005-04-29 |
| JP2010018626A (ja) | 2010-01-28 |
| JPH09505806A (ja) | 1997-06-10 |
| NL300205I2 (nl) | 2006-03-01 |
| NL300205I1 (nl) | 2005-10-03 |
| AU1253495A (en) | 1995-05-08 |
| MXPA94008019A (es) | 2004-08-10 |
| DE69434178D1 (de) | 2005-01-13 |
| DE122005000044I1 (de) | 2005-12-22 |
| FR05C0033I1 (fr) | 2005-09-30 |
| LU91191I2 (fr) | 2005-10-10 |
| DE122005000044I2 (de) | 2007-09-13 |
| IL111240A0 (en) | 1994-12-29 |
| CA2174449C (fr) | 2007-01-16 |
| JP2003160481A (ja) | 2003-06-03 |
| HU9601012D0 (en) | 1996-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9601012D0 (en) | R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof | |
| MX9708977A (es) | Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas. | |
| IL118836A0 (en) | Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan | |
| AU2001273574A1 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
| CA2012876A1 (fr) | Utilisation de l'acide 5-methyle-tetrahydrofolique et de l'acide 5- formyle-tetrahydrofolique dans le traitement des agitations mentales organiques | |
| TW264480B (fr) | ||
| IL111365A0 (en) | (r)-5-carbamoyl -8-fluoro-3-n, n-disubstituted-amino-3, 4-dihydro-2h-1- benzopyrans | |
| AU4333893A (en) | Use of guanosine and its precursors and derivatives in the manufacture of drugs for the treatment of brain dysfunction | |
| IL101560A0 (en) | Condensed diazepinones,their preparation and pharmaceutical compositions containing them | |
| AU3585089A (en) | Condensed diazepinones | |
| Iwasaki et al. | Effects of eperisone hydrochloride on subjective symptoms of eyestrain induced by VDT work. |